Stress-related disorders

PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers

Retrieved on: 
Tuesday, November 14, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, CNS, Allopregnanolone, Schizophrenia, Daphne, Trier social stress test, PureTech Health, Anxiety, Neurosteroid, Patient, Multimedia, LSE, KarXT, Alprazolam, PRTC, Psychiatry, FRCPC, Epilepsy, Pharmacology, Therapy, Benzodiazepine, Stress-related disorders, DSM-IV codes, MPH, University, TSST, Massachusetts General Hospital, Public health, Glyph, Central nervous system, Volunteering, Hospital, Pharmaceutical industry, MD

The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.

Key Points: 
  • The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.
  • View the full release here: https://www.businesswire.com/news/home/20231113556006/en/
    PureTech announced topline results from its Phase 2a, randomized, placebo-controlled, proof-of-concept trial of LYT-300 (oral allopregnanolone).
  • The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.
  • An increase in cortisol levels after the TSST is a physiological response and an objective biomarker of acute stress.

Corporate Wellness Market Size to Grow USD 73640 Million by 2029 at a CAGR of 5.5% | Valuates Reports

Retrieved on: 
Thursday, December 7, 2023
Nutrition, Attention, Lifestyle (social sciences), Mental, Category, Corporation, Employment, Workplace, Growth, USD, Mental health, Health, Stress-related disorders, Compound annual growth rate, Small and medium-sized enterprises, Mindfulness, Knowledge, Risk assessment, Smoking cessation, Pharmaceutical industry, Management, Software

The Corporate Wellness Market is projected to grow from USD 53410 Million in 2023 to USD 73640 Million by 2029, at a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period.

Key Points: 
  • The Corporate Wellness Market is projected to grow from USD 53410 Million in 2023 to USD 73640 Million by 2029, at a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period.
  • Claim Your Free Sample Now:
    Major Factors Driving the Growth of the Corporate Wellness Market:
    The Corporate Wellness Market is enjoying substantial expansion driven by a confluence of factors.
  • North America's corporate wellness market is expanding significantly due to increased attention to employee well-being, healthcare cost management, and technology improvements.
  • Particularly in the United States, there is a developed corporate wellness market with a high rate of program uptake.

Corporate Wellness Market Size to Grow USD 73640 Million by 2029 at a CAGR of 5.5% | Valuates Reports

Retrieved on: 
Thursday, December 7, 2023
Nutrition, Attention, Lifestyle (social sciences), Mental, Category, Corporation, Employment, Workplace, Growth, USD, Mental health, Health, Stress-related disorders, Compound annual growth rate, Small and medium-sized enterprises, Mindfulness, Knowledge, Risk assessment, Smoking cessation, Pharmaceutical industry, Management, Software

The Corporate Wellness Market is projected to grow from USD 53410 Million in 2023 to USD 73640 Million by 2029, at a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period.

Key Points: 
  • The Corporate Wellness Market is projected to grow from USD 53410 Million in 2023 to USD 73640 Million by 2029, at a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period.
  • Claim Your Free Sample Now:
    Major Factors Driving the Growth of the Corporate Wellness Market:
    The Corporate Wellness Market is enjoying substantial expansion driven by a confluence of factors.
  • North America's corporate wellness market is expanding significantly due to increased attention to employee well-being, healthcare cost management, and technology improvements.
  • Particularly in the United States, there is a developed corporate wellness market with a high rate of program uptake.

Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD

Retrieved on: 
Wednesday, October 11, 2023
Post-traumatic stress disorder, Therapy, PTSD, Biomarker, SILO, Plasma protein binding, Anxiety, Columbia University, Stress-related disorders, Research, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The study will evaluate the human factor interface and usability of SPC-15’s intranasal formulation in combination with a nose-to-brain delivery mechanism.

Key Points: 
  • ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).
  • The study will evaluate the human factor interface and usability of SPC-15’s intranasal formulation in combination with a nose-to-brain delivery mechanism.
  • “The human factors study is an important step as we prepare and plan to enter the clinic with SPC-15 for the treatment of PTSD and stress-related disorders,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University pursuant to a sponsored research agreement and option.

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Retrieved on: 
Wednesday, September 20, 2023
Columbia University, Therapy, Anxiety, Drug discovery, Biopharmaceutical, Disorder, Stress-related disorders, FDA, SILO, IND, Pharmacology, PTSD, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with the preparation of a pre-Investigational New Drug (IND) package and meeting request with the United States Food and Drug Administration (FDA). SPC-15 is a targeted intranasal prophylactic intended for the treatment and prevention of anxiety, PTSD, and other stress-related disorders. 

Key Points: 
  • SPC-15 is a targeted intranasal prophylactic intended for the treatment and prevention of anxiety, PTSD, and other stress-related disorders.
  • “Our pre-clinical data indicate that SPC-15 has additive benefits for combating stress-induced pathophysiology, both at the behavioral and neural levels.
  • In conjunction with Columbia University, we are pleased to announce this milestone in advancing our potential therapeutic development for those suffering from stress-induced anxiety and PTSD.
  • A pre-IND meeting request for collaborative discussions with the FDA will be filed early 2024
    SPC-15 utilizes metabolic biomarker profiling to treat anxiety, PTSD, and other stress-related disorders.

Mental illness in fathers may increase the risk of preterm birth – new research

Retrieved on: 
Thursday, July 20, 2023
Association, Pregnancy, Depression, Mental disorder, DSM-IV codes, Schizophrenia, Gestational age, Spectrum, Parent, Social support, Prenatal care, PLOS Medicine, Woman, Research, Mother, Stress-related disorders, Death, Anxiety disorder, Post-traumatic stress disorder, Risk, Child, Epigenetics of anxiety and stress–related disorders, Preterm birth, Investor, Father, Antenatal depression, Diagnosis, Smoking, Mental health, Substance abuse, Nursing, Birth control, Residential care, Dietary supplement

But the risk of preterm birth can also be affected by a father’s mental health.

Key Points: 
  • But the risk of preterm birth can also be affected by a father’s mental health.
  • In our new study published in the journal PLOS Medicine, we found that fathers’ mental illness increases the risk of preterm birth and that the risk is even greater when both parents are affected.

1.5 million babies

    • We included data on 1.5 million infants born in Sweden between 1997 and 2016.
    • We obtained information about the parents’ mental health from the National Patient Register, which records all psychiatric diagnoses by clinical specialists in Sweden.
    • We ascertained length of pregnancies in weeks (gestational age) from the Medical Birth Register where all Swedish births are recorded.
    • Some 15% of the infants had at least one parent with a mental health disorder.

Why the link?

    • Our study demonstrates the significance of a father’s mental illness in the risk of preterm birth.
    • The underlying mechanism is likely to be complex – we can only really speculate on what is behind these trends.
    • Suffering from a mental illness, or having a partner with a mental illness, will probably be a source of stress for an expectant mother.

Napping may be beneficial for your brain – here's how

Retrieved on: 
Tuesday, June 27, 2023
Biobank, UK Biobank, Siderian, Profile, Deficit spending, Nap, Brain, Research, Dementia, Stress-related disorders, MRI, Marker beacon, Ageing, Memory, Hippocampus, Leather, Design, Medical imaging, Sleep

Napping also appears to be beneficial to the brain – with research showing that even brief naps of 5-15 minutes can instantly improve how well you perform mentally.

Key Points: 
  • Napping also appears to be beneficial to the brain – with research showing that even brief naps of 5-15 minutes can instantly improve how well you perform mentally.
  • Our study aimed to uncover the potential causal relationship between daytime napping, cognitive function and brain volume.
  • We discovered that people who had genetic variations associated with napping also had larger total brain volume on average.
  • Our findings help clarify the impact of daytime napping on brain health, which may limit cognitive decline as a person ages.

Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders

Retrieved on: 
Wednesday, April 19, 2023
Columbia University, National Center for Telehealth & Technology, Depression, Therapy, Anxiety, Deficit spending, Research, Stress-related disorders, Anxiety disorder, Patent, Ageing, SILO, PTSD, World Health Organization, Pharmaceutical industry

Development of the drug formulation is pursuant to the Company’s sponsored research agreement with Columbia University.

Key Points: 
  • Development of the drug formulation is pursuant to the Company’s sponsored research agreement with Columbia University.
  • Preclinical studies in the field suggest that SPC-15 could be a promising therapeutic target for the treatment of cognitive impairment, PTSD, and stress-related disorders.
  • “We are advancing our development of SPC-15 through this formulation and feasibility study investigating dose strengths and delivery,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • Silo Pharma was recently granted a U.S. patent covering SPC-15 as a method for the treatment and prevention of stress-induced affective disorders in females.

New book sheds light on chronic pain-stress connection

Retrieved on: 
Tuesday, April 4, 2023
CSS, X-ray, Back injury, Chronic pain, Depression, Irritable bowel syndrome, Brain, Neck, Pain, Magnetic resonance imaging, Patient, Stress-related disorders, Chemical oxygen demand, Nervous system, Fibromyalgia, Diagnosis, Panic, Migraine, Nursing, Medical imaging

SCOTTSDALE, Ariz., April 4, 2023 /PRNewswire/ -- Thirty million people in the United States suffer from a condition that causes chronic pain, but conventional medical testing doesn't show the source of the problem. Central sensitization syndrome (CSS) stems from a dysfunction in the nervous system, where over-reactive nerves send exaggerated pain signals. Chronic back, neck, and stomach pain, irritable bowel syndrome, fibromyalgia, migraines, and bladder pain are types of CSS.

Key Points: 
  • Central sensitization syndrome (CSS ) stems from a dysfunction in the nervous system, where over-reactive nerves send exaggerated pain signals.
  • Chronic back, neck, and stomach pain, irritable bowel syndrome, fibromyalgia, migraines, and bladder pain are types of CSS.
  • A new book sheds light on the condition, including how stress can escalate the pains.
  • Sunbreak , by Dr. Shana Johnson , explains CSS and the reasons the conditions are so difficult to diagnose.

Forests Reduce Health Risks, New Global Report Confirms

Retrieved on: 
Tuesday, March 21, 2023
Human, Depression, University, Diabetes, Albert Einstein's brain, Tree, Health, Cancer, Malaria, Forest, International Science Council, Stress-related disorders, Recreation, Nature, Risk, International Union of Forest Research Organizations, University of British Columbia, Longevity, Relaxation, Disease, IUFRO, Organization, Agriculture

The outcome is presented in a major report titled "Forests and Trees for Human Health: Pathways, Impacts, Challenges and Response Options" by the Global Forest Expert Panels (GFEP) Programme of the International Union of Forest Research Organizations (IUFRO).

Key Points: 
  • The outcome is presented in a major report titled "Forests and Trees for Human Health: Pathways, Impacts, Challenges and Response Options" by the Global Forest Expert Panels (GFEP) Programme of the International Union of Forest Research Organizations (IUFRO).
  • The assessment finds that existing evidence strongly supports a wide range of physical, mental, social and spiritual health benefits associated with forests and green spaces.
  • "The report suggests that decision-makers in forest, health and related domains should adopt more integrative perspectives for addressing forest-human health relations.
  • By linking forest and human health policies and strategies, new and innovative solutions for health and forest challenges can be identified", says Chair of the GFEP on Forests and Human Health, Dr. Cecil Konijnendijk, University of British Columbia, Canada.